PDF(Pubmed)
Abstract：
UNASSIGNED: Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent and critical side effects due to chemotherapeutics. In China, Xiao-Ban-Xia-Tang (XBXT) has already been applied extensively to prevent and treat CINV. However, there is limited testimony on the effectiveness and safety of this purpose, and there was no correlative systematic review. The aim of this review was to systematically evaluate the effectiveness and safety of XBXT in preventing and treating CINV.
UNASSIGNED: The systematic search was conducted in eight databases to acquire randomized controlled trials (RCTs) that appraised the effect of XBXT in treating CINV. The vomiting and nausea relief efficiency, eating efficiency, quality of life, and adverse reactions were explored for efficacy assessment. Bias risk was rated by manipulating the Cochrane risk of bias tool 2.0 (RoB 2). The retrieved investigations were analyzed by utilizing ReviewManager 5.4 and Stata 17.0. The quality of evidence was evaluated adopting the GRADE tool.
UNASSIGNED: A total of 16 clinical RCTs of XBXT in the treatment of CINV were incorporated into the investigation, with a total of 1246 participants. The meta-analysis showed that compared with conventional antiemetic drugs, XBXT and antiemetics improved the vomiting relief efficiency (RR 1.35, 95% confidence interval: 1.25-1.46, p < 0.00001), nausea relief efficiency (N = 367, RR 1.23, 95% CI: 1.09-1.38, p < 0.00001), and quality of life (RR = 1.37, 95% CI: 1.14-1.65, p = 0.0009) and reduced the adverse events (N = 370, RR 0.53, 95% CI: 0.29-0.96, p = 0.04). XBXT and DARAs raised eating efficiency compared with DARAs (N = 208, RR 1.30, 95% CI: 1.07-1.57, p = 0.007). The data existed as statistically significant, and the publication bias was identified as relatively low from the funnel plot and trim and fill analysis. In addition, sensitivity analysis demonstrated robust outcomes. The quality of evidence for each outcome ranged from moderate to high.
UNASSIGNED: There is some encouraging evidence that XBXT and antiemetics had better therapeutic effects and safety in treating CINV than antiemetic drugs alone. The quality assessment and low publication bias indicated that the overall criterion was scientific. Better research is required to verify the evidence designed with large-scale RCTs and rigorous methods.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=281046.
UNASSIGNED: The systematic search was conducted in eight databases to acquire randomized controlled trials (RCTs) that appraised the effect of XBXT in treating CINV. The vomiting and nausea relief efficiency, eating efficiency, quality of life, and adverse reactions were explored for efficacy assessment. Bias risk was rated by manipulating the Cochrane risk of bias tool 2.0 (RoB 2). The retrieved investigations were analyzed by utilizing ReviewManager 5.4 and Stata 17.0. The quality of evidence was evaluated adopting the GRADE tool.
UNASSIGNED: A total of 16 clinical RCTs of XBXT in the treatment of CINV were incorporated into the investigation, with a total of 1246 participants. The meta-analysis showed that compared with conventional antiemetic drugs, XBXT and antiemetics improved the vomiting relief efficiency (RR 1.35, 95% confidence interval: 1.25-1.46, p < 0.00001), nausea relief efficiency (N = 367, RR 1.23, 95% CI: 1.09-1.38, p < 0.00001), and quality of life (RR = 1.37, 95% CI: 1.14-1.65, p = 0.0009) and reduced the adverse events (N = 370, RR 0.53, 95% CI: 0.29-0.96, p = 0.04). XBXT and DARAs raised eating efficiency compared with DARAs (N = 208, RR 1.30, 95% CI: 1.07-1.57, p = 0.007). The data existed as statistically significant, and the publication bias was identified as relatively low from the funnel plot and trim and fill analysis. In addition, sensitivity analysis demonstrated robust outcomes. The quality of evidence for each outcome ranged from moderate to high.
UNASSIGNED: There is some encouraging evidence that XBXT and antiemetics had better therapeutic effects and safety in treating CINV than antiemetic drugs alone. The quality assessment and low publication bias indicated that the overall criterion was scientific. Better research is required to verify the evidence designed with large-scale RCTs and rigorous methods.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=281046.
摘要：
■化疗引起的恶心和呕吐（CINV）是化疗引起的最常见和最严重的副作用之一。在中国,小班夏汤（XBXT）已被广泛应用于NV的预防和治疗。然而,关于这一目的的有效性和安全性的证词有限，没有相关的系统评价。本综述旨在系统评价XBXT预防和治疗CINV的有效性和安全性。
■在八个数据库中进行了系统搜索，以获得评估XBXT治疗CINV效果的随机对照试验（RCT）。呕吐和恶心的缓解效率，吃效率，生活质量,并对不良反应进行疗效评估。通过操纵Cochrane偏倚风险工具2.0(RoB2)来评估偏倚风险。利用ReviewManager5.4和Stata17.0对检索到的调查进行了分析。采用GRADE工具对证据质量进行评估。
■在CINV治疗中，共有16项XBXT临床随机对照试验被纳入研究，共有1246名参与者。荟萃分析表明,与常规止吐药相比,XBXT和止吐药提高了呕吐缓解效率（RR1.35，95％置信区间：1.25-1.46，p<0.00001），恶心缓解效率（N=367，RR1.23，95％CI：1.09-1.38，p<0.00001），和生活质量（RR=1.37，95％CI：1.14-1.65，p=0.0009），并减少了不良事件（N=370，RR0.53，95％CI：0.29-0.96，p=0.04）。与DARAs相比，XBXT和DARAs提高了进食效率（N=208，RR1.30，95％CI：1.07-1.57，p=0.007）。数据具有统计学意义，从漏斗图和修剪和填充分析中确定出版偏倚相对较低。此外,敏感性分析显示出稳健的结果。每个结果的证据质量从中等到高不等。
■有一些令人鼓舞的证据表明，XBXT和止吐剂在治疗CINV方面比单独止吐药物具有更好的治疗效果和安全性。质量评估和低发表偏倚表明总体标准是科学的。需要更好的研究来验证使用大规模RCT和严格方法设计的证据。
系统审查注册：https://www。crd.约克。AC.uk/PROSPERO/display_record。php?RecordID=281046。
■在八个数据库中进行了系统搜索，以获得评估XBXT治疗CINV效果的随机对照试验（RCT）。呕吐和恶心的缓解效率，吃效率，生活质量,并对不良反应进行疗效评估。通过操纵Cochrane偏倚风险工具2.0(RoB2)来评估偏倚风险。利用ReviewManager5.4和Stata17.0对检索到的调查进行了分析。采用GRADE工具对证据质量进行评估。
■在CINV治疗中，共有16项XBXT临床随机对照试验被纳入研究，共有1246名参与者。荟萃分析表明,与常规止吐药相比,XBXT和止吐药提高了呕吐缓解效率（RR1.35，95％置信区间：1.25-1.46，p<0.00001），恶心缓解效率（N=367，RR1.23，95％CI：1.09-1.38，p<0.00001），和生活质量（RR=1.37，95％CI：1.14-1.65，p=0.0009），并减少了不良事件（N=370，RR0.53，95％CI：0.29-0.96，p=0.04）。与DARAs相比，XBXT和DARAs提高了进食效率（N=208，RR1.30，95％CI：1.07-1.57，p=0.007）。数据具有统计学意义，从漏斗图和修剪和填充分析中确定出版偏倚相对较低。此外,敏感性分析显示出稳健的结果。每个结果的证据质量从中等到高不等。
■有一些令人鼓舞的证据表明，XBXT和止吐剂在治疗CINV方面比单独止吐药物具有更好的治疗效果和安全性。质量评估和低发表偏倚表明总体标准是科学的。需要更好的研究来验证使用大规模RCT和严格方法设计的证据。
系统审查注册：https://www。crd.约克。AC.uk/PROSPERO/display_record。php?RecordID=281046。
